A decade after the US Food and Drug Administration required makers of extended-release and long-acting opioid analgesics to conduct a post-marketing study on the risk of opioid-induced hyperalgesia, manufacturers and the agency have a proposed protocol for review by its outside experts.
The agency’s Anesthetic and Analgesic Drug Products Advisory Committee will discuss the protocol at its 19 April meeting. In its...





